Skip to main content
Smart Investors Daily
ND

NASDAQ · NDRA

ENDRA Life Sciences Inc.

Healthcare · Medical - Diagnostics & Research

$3.70

Down-$0.04 (-1.08%)

Updated Nov 20, 2026, 4:29 PM

SID Score

2.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
4.46M
P/E ratio
-0.56
Dividend yield
0.00%
52-week range
$2.96 – $6.80
Volume
18.75K
Avg. volume
305.03K

Price performance · NDRA

NDRA price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 19, 2026

NDRA closed at $3.70 after 21 trading sessions, down 22.59% for the selected period.

Last close
$3.70
Period change
-22.59%
Period low
$3.70
Period high
$5.01
Daily close
View OHLC price history
NDRA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 19, 2026$3.985$4.065$3.5806$3.7018.75K
Nov 18, 2026$3.97$4.055$3.525$4.03514.08K
Nov 17, 2026$4.4054$4.4099$3.44$3.9216.97K
Nov 16, 2026$4.41$4.46$4.32$4.424.49K
Nov 13, 2026$4.51$4.53$4.41$4.414.58K
Nov 12, 2026$4.65$4.96$4.59$4.647.42K
Nov 11, 2026$4.77$4.80$4.6366$4.76885.51K
Nov 10, 2026$4.78$5.14$4.77$4.7710.14K
Nov 9, 2026$4.75$4.892$4.71$4.844.21K
Nov 6, 2026$4.98$4.98$4.70$4.731.2K
Nov 5, 2026$4.98$5.005$4.00$5.00517.14K
Nov 4, 2026$4.75$4.96$4.75$4.947.37K
Nov 3, 2026$4.8302$4.945$4.745$4.863.74K
Nov 2, 2026$4.71$4.885$4.64$4.805.78K
Oct 30, 2026$4.85$4.86$4.7225$4.7510.57K
Oct 29, 2026$4.91$5.185$4.69$4.8814.64K
Oct 28, 2026$4.96$5.01$4.58$4.7410.5K
Oct 27, 2026$4.80$5.00$4.72$4.9615.3K
Oct 26, 2026$4.83$4.98$4.735$4.8212.86K
Oct 23, 2026$4.68$4.80$4.655$4.804.52K
Oct 22, 2026$4.80$4.915$4.562$4.7810.82K

Latest NDRA news

The latest Smart Investors Daily articles mentioning NDRA.

NDRA research

Overview

Company profile and research snapshot.

Company profile

ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI at the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
NDRA recent ratings
DateFirmRatingTarget
Jun 1, 2026Ascendiant CapitalBuy—
Dec 8, 2025Ascendiant CapitalBuy—
Sep 22, 2025Ascendiant CapitalBuy—
May 30, 2025Ascendiant CapitalBuy—
Apr 21, 2025Ascendiant CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Benzinga · Aug 17, 2026

ENDRA Life Sciences Q2 EPS $0.06 Beats $(0.84) Estimate

ENDRA Life Sciences (NASDAQ:NDRA) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $(0.84) by 107.14 percent. This is a 103.51 percent increase over losses of $(1.71) per share

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.